2014_SGI-110_poster_ASCO_abst_7030_Griffiths-draft_v6

First Page		Document Content
Date: 2014-06-09 09:25:29 Myeloid leukemia Nucleosides Triazines Acute myeloid leukemia Azacitidine Hypomethylating agent Decitabine DNA demethylation Leukemia Oncology Medicine Acute leukemia		2014_SGI-110_poster_ASCO_abst_7030_Griffiths-draft_v6 Add to Reading List Source URL: astx.com Download Document from Source Website File Size: 1,06 MB Share Document on Facebook

	Ratio of involved/uninvolved immunoglobulin quantification by Hevylite™ assay: clinical and prognostic impact in multiple myeloma DocID: 15uOM - View Document
	HIGHLIGHTS OF PRESCRIBING INFORMATION DocID: 13My6 - View Document
$June 14, 2013 Astex Pharmaceuticals Announces Presentation of Updated Results of SGI[removed]Study in Patients With Intermediate or High Risk Relapsed or Refractory Myelodysplastic Syndromes at the European Hematology As$	June 14, 2013 Astex Pharmaceuticals Announces Presentation of Updated Results of SGI[removed]Study in Patients With Intermediate or High Risk Relapsed or Refractory Myelodysplastic Syndromes at the European Hematology As DocID: 11odm - View Document
	Abst. No. Outcomes of Intermediate or High Risk Myelodysplastic Syndromes (MDS) Patients Post Azacitidine and/or Decitabine Treatment Failures with SGI-110, a Novel Second Generation Hypomethylating Agent (HMA) DocID: 10gfI - View Document
$DNA demethylation activity over time and safety of 3 different dose-escalation regimens of SGI-110, a novel subcutaneous (SQ) hypomethylating agent (HMA), in the treatment of relapsed/refractory patients with MDS and AML$	DNA demethylation activity over time and safety of 3 different dose-escalation regimens of SGI-110, a novel subcutaneous (SQ) hypomethylating agent (HMA), in the treatment of relapsed/refractory patients with MDS and AML DocID: Z1WQ - View Document